US 10,472,371 B2Granted

Compositions for activating pyruvate kinase

AssigneeFORMA Therapeutics, Inc.

InventorsXiaozhang Zheng, Neal Green, Gary Gustafson, David R. Lancia, Jr., Lorna Mitchell, Tatiana Shelekhin

Life of this patent

Estimating the term…

Abstract

Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).

Claims3

Dependent claims

A composition comprising compound 2:

Dependencies are inferred from the claim text.

Facts

Application: 16/245,654Filed 11 Jan 2019 · continuation
Priority: 20 Mar 2017
Published: US 2019/0218221 A118 Jul 2019
Granted: 12 Nov 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 31/407
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: condensed with other…
A61P 7/00
Drugs for disorders of the blood or the extracellular fluid

Family

Application62/473,751Us provisional application · filed 20 Mar 2017
Application15/926,236Parent of this continuation · filed 20 Mar 2018
US 2019/0218221 A1Pre-grant publication · published 18 Jul 2019
US 10,208,052 B1Parent of this continuation
US 10,472,371 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results